Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 14/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 7/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19827028 | 0.88 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL19826941 | 0.87 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL16947092 | 0.84 | NTRK1 (0.46) | NTRK1NTRK3NTRK2JAK2 | |
| SCHEMBL29422688 | 0.79 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL19827083 | 0.79 | NTRK1 (0.41) | NTRK1NTRK3NTRK2TGFBR1IRAK4 | |
| SCHEMBL29422764 | 0.79 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL29422547 | 0.79 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL22695326 | 0.79 | NTRK1 (0.38) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL22688714 | 0.78 | NTRK1 (0.40) | NTRK1NTRK3NTRK2JAK2ADORA3 | |
| SCHEMBL22688782 | 0.78 | NTRK1 (0.38) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689400-B2 | Macrocycle kinase inhibitors | Turning Point Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190169208-A1 | MACROCYCLE KINASE INHIBITORS | TP THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| WO-2018022911-A1 | MACROCYCLE KINASE INHIBITORS | TP THERAPEUTICS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169208-A1 | MACROCYCLE KINASE INHIBITORS | DCK, MAP3K20, PLK1 | NTRK1 964/4885NTRK3 790/4885NTRK2 1605/4885 |
| US-10689400-B2 | Macrocycle kinase inhibitors | DCK, MAP3K20, PLK1 | NTRK1 964/4885NTRK3 790/4885NTRK2 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.